The invention relates to products and methods for treating Crohn’s disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12 through the specific binding to the p19 subunit. In particular, the present invention relates to the use of an anti-IL-23 antibody defined by heavy chain CDRs SYGMH, VIWYDGSNEYYADSVKGR, and DRGYTSSWYPDAFDI and the light chain CDRs TGSSSNTGAGYDVH, GSGNRPS, and QSYDSSLSGWV for the treatment of Crohn’s disease. This antibody is to be administered using particular dosage regimes. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with mild to severe Crohn’s disease.
